Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 12, 721 (2006)
Published online: 28 June 2006 | doi:10.1038/nm0706-721a
Eyebrows raised over extended age range for cervical cancer vaccine
Meredith Wadman1
- Washington, DC
Abstract
Experts are skeptical about the vaccine's use in older women.
At the high-profile meeting of the American Society of Clinical Oncology in June, the pharmaceutical giant GlaxoSmithKline (GSK) made a carefully timed presentation. The company showed data demonstrating that Cervarix, its cervical cancer vaccine, "is highly immunogenic and well tolerated in women over 25 years of age.
To read this story in full you will need to login or make a payment (see right).
